How Can we Improve Outcomes for the Elderly Patient with AML?

The Challenge of Managing Older Patients With AML: EUROCARE-5 (2000-2007)

Front-Line Treatment Outcomes in Older Patients With AML

Poorer Outcomes With Undertreatment of Older Patients

Clinical and Biological Factors Affecting Treatment Outcomes

Case #1: Fit Elderly Patient With Favorable-Risk Cytogenetics

Treating Fit Patients With Favorable-Risk Cytogenetics

Case #2: Fit Elderly Patient With Poor-Risk Cytogenetics

Treating Fit Patients With Poor-Risk Cytogenetics

Treating Fit Patients With Poor-Risk Cytogenetics (cont.)

Considerations in Selecting a Treatment Option

Effect of Antecedent Hematologic Disease Other Than MDS on Outcomes Danish National Acute Leukemia Registry

Decitabine in AML: Multicenter DACO-016 Phase 3 Trial

DACO-016: OS Analysis By Time Point

Azacitidine in AML 20-30 and AML 30+: Austrian Azacitidine Registry

Azacitidine in Older Patients With AML 30+: Multicenter AZA-AML-001 Phase 3 Trial

AZA-AML-001: Analysis by CCR Treatment

AZA-AML-001: Analysis of Patients With AML-MRC by CCR Treatment

Hematologic Response With Hypomethylating Agents: DACO-016 and AZA-AML-001

Case #3: Unfit Elderly Patient With Comorbidities

Treating Unfit Elderly Patients

Selecting a Hypomethylating Agent in AML: Evidence From MDS

Selecting a Hypomethylating Agent in AML: DACO-016, AZA-AML-001, and Austrian Azacitidine Registry

Assessing Response to Hypomethylating Agents

Managing Toxicities Associated With Hypomethylating Agents

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)